**SUPPLEMENTAL MATERIAL**

# Supplemental Figure 1. Distribution of patients by disease activity category. MBDA score, DAS28-CRP, and CRP were measured at baseline for Leiden (N=163, 156, 156, respectively), OPERA (N=164) and SWEFOT (N=235). MBDA score and DAS28-CRP were measured at year 1 for AMPLE arm 1 (abatacept; N=181[17], 187[16] respectively) and AMPLE arm 2 (adalimumab; N=186[17], 190[16] respectively). CRP data were not available for AMPLE for these analyses. Timepoints are those used in prior reports of the relationship between MBDA score and radiographic progression and in the present analyses (see Table 1).

